Vitae Pharmaceuticals Inc., a drug discovery company partnered with Boehringer Ingelheim GmbH on its development-stage diabetes and Alzheimer's therapies, has filed to raise up to $55 million in an initial public offering (IPO), raising the total of global life sciences IPOs completed or pending this year to 91.